AnGes Inc - Company Profile
Powered by 
All the data and insights you need on AnGes Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date AnGes Inc Strategy Report
- Understand AnGes Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
AnGes Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of AnGes Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 20 Aug 2018 | Lorem |
| Vasomune and AnGes open to CRO/CMO offers to run Phase I and II critical care lung condition trial, decisions in 2019, CEO says | 20 Aug 2018 | Arafa Salam |
| AnGes in active talks to partner Phase III critical limb ischemia drug by YE18, Phase Ib back pain program by 1H19 – COO | 29 Sep 2017 | Shuan Sim |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer